A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Faricimab (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms YOSEMITE
- Sponsors Chugai Pharmaceutical; Roche
- 29 Oct 2019 Planned End Date changed from 2 Jun 2022 to 30 Sep 2021.
- 29 Oct 2019 Planned primary completion date changed from 30 Sep 2021 to 30 Sep 2020.
- 04 Oct 2019 Status changed from recruiting to active, no longer recruiting.